UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment
of Gaucher Disease

CARMIEL, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the Mexican Federal
Commission for the Protection against Sanitary Risk (COFEPRIS) and the Public
Health Institute of Chile have both granted regulatory approval to UPLYSO™
(alfataliglicerase) for the long-term enzyme replacement therapy for adults
with a confirmed diagnosis of Type I Gaucher disease. UPLYSO will be marketed
in Mexico and Chile by Pfizer Inc., the Company's commercialization partner.

UPLYSO is known as ELELYSO™ (taliglucerase alfa) outside of Latin America.
Taliglucerase alfa was approved by the U.S. Food and Drug Administration in
May 2012 and subsequently has been approved by Israel's Ministry of Health,
Brazil's ANVISA and by the regulatory authorities of other countries.

"We are very happy that UPLYSO may now be made available as an additional
treatment alternative to Gaucher patients in Mexico and Chile," stated Dr.
Raul Chertkoff, the Company's Vice President, Medical Affairs."Including
Mexico and Chile, UPLYSO has been reviewed and approved by six different
regulatory authorities across the globe.Through our joint efforts with
Pfizer, we are working on expanding the commercial potential for UPLYSO in
additional countries."

UPLYSO is the first plant cell-based ERT for the treatment of Gaucher disease.
It is also the first approved plant cell-expressed drug that is derived from
ProCellEx^®, the Company's proprietary plant cell-based protein manufacturing
system, using genetically engineered carrot cells. UPLYSO is a form of the
human lysosomal enzyme, glucocerebrosidase, used to treat Gaucher disease.

On November 30, 2009, the Company entered into an agreement with Pfizer to
develop and commercialize taliglucerase alfa/alfataliglicerase. Under the
terms of the agreement, the Company retained the exclusive commercialization
rights in Israel, while Pfizer received exclusive licensing rights for
commercialization in all other markets.

Indication for ELELYSO in the United States

ELELYSO™ (taliglucerase alfa) for injection is a hydrolytic lysosomal
glucocerebroside-specific enzyme indicated for long-term enzyme replacement
therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.

Important Safety Information for ELELYSO in the United States

As with any intravenous protein medicine, like enzyme replacement therapy
(ERT), severe allergic reactions (including anaphylaxis) have been observed in
patients treated with ELELYSO. If this occurs, ELELYSO should be immediately
discontinued, and appropriate medical treatment should be initiated. Patients
who have experienced anaphylaxis to ELELYSO or another ERT should proceed with
caution upon retreatment.

In addition, infusion reactions (including allergic reactions)—defined as a
reaction occurring within 24 hours of the infusion—were the most commonly
observed reactions to ELELYSO. The most commonly observed infusion reactions
were headache, chest pain or discomfort, weakness, fatigue, hives, abnormal
redness of the skin, increased blood pressure, back or joint pain, and
flushing. Other infusion or allergic reactions included swelling of the face,
mouth, and/or throat; wheezing; shortness of breath; skin color turning blue;
coughing; and low blood pressure. Most of these reactions were mild and did
not require treatment.

Management of infusion reactions is based on the type and severity of the
reaction. Your doctor may manage infusion reactions by temporarily stopping
the infusion, slowing the infusion rate, or treating with medications such as
an antihistamine and/or a fever reducer. Treatment with antihistamines and/or
corticosteroids prior to infusion with ELELYSO may prevent these reactions.

Other common adverse reactions observed were upper respiratory tract
infections, throat infection, flu, urinary tract infection, and pain in
extremities.

As with all therapeutic proteins, including ERTs, there is a possibility of
developing antibodies to ELELYSO. However, it is currently unclear whether
this has an impact on the clinical response or adverse reactions. Patients
with an immune response to other ERTs who are switching to ELELYSO should
continue to be monitored for antibodies. Comparison of the frequency of
antibodies across ERTs may be misleading. Patients who have developed infusion
or immune reactions with ELELYSO or with another ERT should be monitored for
antidrug antibodies when being treated with ELELYSO.

If you are pregnant, or plan to become pregnant, you should talk to your
doctor about potential benefits and risks.

The health information contained herein is provided for educational purposes
only and is not intended to replace discussions with a health care provider.
All decisions regarding patient care must be made with a health care provider,
considering the unique characteristics of the patient.

This product information is intended only for residents of the United States.

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Gaucher Disease

Gaucher disease is an inherited lysosomal storage disorder in humans that
affects an estimated 10,000 people worldwide and can cause severe and
debilitating symptoms, including: enlargement of the liver and spleen, various
forms of bone disease, easy bruising, and anemia (a low number of red blood
cells). Gaucher disease consists of varying degrees of severity; it has been
sub-divided into three subtypes - Types 1, 2, and 3 - according to the
presence or absence of neurological involvement. Type 1, the most common, is
found at a higher frequency among individuals who are of Ashkenazi Jewish
ancestry.

About ELELYSO (taliglucerase alfa)

ELELYSO (taliglucerase alfa) for injection is a hydrolytic lysosomal
glucocerebroside-specific enzyme indicated for long-term enzyme replacement
therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.

Protalix BioTherapeutics Inc.

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx^®.Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.Protalix's first
product manufactured by ProCellEx, taliglucerase alfa, was approved for
marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by
Israel's Ministry of Health in September 2012, by the Brazilian National
Health Surveillance Agency (ANVISA) in March 2013 and by the regulatory
authorities of other countries. Marketing applications for taliglucerase alfa
have been filed in additional territories as well.Protalix has partnered with
Pfizer Inc. for the worldwide development and commercialization of
taliglucerase alfa, excluding Israel, where Protalix retains full
rights.Protalix's development pipeline also includes the following product
candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A
protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant
human acetylcholinesterase in development for several therapeutic and
prophylactic indications, a biodefense program and an organophosphate-based
pesticide treatment program; an orally-delivered glucocerebrosidase enzyme
that is naturally encased in carrot cells, also for the treatment of Gaucher
disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for
the treatment of certain immune diseases such as rheumatoid arthritis,
juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and
plaque psoriasis; and others.

Forward Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe-harbor provisions of the Private Securities Litigation Reform Act of
1995.The terms "anticipate," "believe," "estimate," "expect," "plan" and
"intend" and other words or phrases of similar import are intended to identify
forward-looking statements.These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made.These
statements are based on our current beliefs and expectations as to such future
outcomes.Drug discovery and development involve a high degree of
risk.Factors that might cause material differences include, among others:
risks and uncertainties related to the timing of a commercial launch and
market acceptance of taliglucerase alfa in Mexico and Chile; risks relating to
the review process of other foreign regulatory and other governmental bodies;
risks relating to delays in other foreign regulatory authorities' approval of
any applications filed for taliglucerase alfa or refusals to approve such
filings; the risk that applicable regulatory authorities may refuse to approve
the marketing and sale of a drug product even after acceptance of an
application filed for the drug product; the dependence on performance by third
party providers of services and supplies relating to the commercialization of
taliglucerase alfa in Mexico and Chile; the inherent risks and uncertainties
in developing drug platforms and products of the type we are developing; the
impact of development of competing therapies and/or technologies by other
companies and institutions; potential product liability risks, and risks of
securing adequate levels of product liability and other necessary insurance
coverage; and other factors described in our filings with the U.S. Securities
and Exchange Commission.The statements in this release are valid only as of
the date hereof and we disclaim any obligation to update this information.

CONTACT: Investor Contact
        
         Marcy Nanus
         The Trout Group, LLC
         646-378-2927
         mnanus@troutgroup.com
        
         Media Contact
        
         Jennifer Conrad or Kari Watson
         MacDougall Biomedical Communications
         781-235-3060
         jconrad@macbiocom.com
         kwatson@macbiocom.com